Cancer News and Research

Latest Cancer News and Research

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Prostate cancer screening: Another set of new guidelines adds to the confusion

Members of America's Prostate Cancer Organizations are concerned that the issuance this morning of yet another set of new guidelines on screening for prostate cancer is only adding to the confusion most men already feel about whether they should or shouldn't be tested for the most common form of cancer in American men.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Cryoablation kills breast tumors in mice

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

New federal guidelines on breast cancer screening: Stanford experts disagree

At a recent community education program, Stanford experts on women’s cancer disagreed with controversial new federal guidelines on breast cancer screening. The new guidelines, released in November by the U.S. Preventive Services Task Force, would delay a woman’s first mammogram by 10 years, reduce future screenings from annual to every other year, and end them after age 74.

4 Mar 2010

Elsevier releases special issue to mark the 25th anniversary of antiretroviral drug development

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, released a special issue of the journal Antiviral Research (www.sciencedirect.com/science/journal/01663542), marking the 25th anniversary of antiretroviral drug development.

4 Mar 2010

Bozeman Deaconess Hospital enters into affiliation agreement with SCCA Network

Bozeman Deaconess Hospital in Bozeman, Montana, has joined the Seattle Cancer Care Alliance Network to become the ninth Northwest community healthcare facility to enter into an affiliation agreement with the SCCA. The SCCA Network provides a structured program for supporting community-based oncology services to advance the level of care, including making leading-edge clinical trials available to local patients and offering continuing medical education to local health care providers.

4 Mar 2010

Researchers demonstrate the safety of potential vaccine against mesothelioma

Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Cystoscopy: Cost-effective method of detecting tumors

In a new study from The University of Texas M. D. Anderson Cancer Center, researchers found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumors.

4 Mar 2010

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Older women who have had breast cancer surgery have a greater risk of the cancer returning if they delay their post-surgical radiation treatment, report Dana-Farber Cancer Institute scientists.

4 Mar 2010

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning’s ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.

4 Mar 2010

Study on role of recorded ODLs in improving clinical care for low-weight babies: RWJF awards $480,000 grant

Researchers at Charles Drew University of Medicine and Science and UC Irvine will monitor the day-to-day health of low-birth-weight babies and their parents as part of a comprehensive initiative designed to combat chronic illnesses associated with low-weight births.

4 Mar 2010

Belatacept drug can prevent graft rejection in kidney transplant recipients

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

4 Mar 2010

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

ExonHit Therapeutics today reported the signing by Allergan, Inc. and Bristol-Myers Squibb Company of a global exclusive license agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323), ExonHit’s lead compound from the most advanced program of its collaboration with Allergan.

4 Mar 2010

Biomoda and Amigenics collaborate to advance treatments for lung and other cancer

Biomoda, Inc. (www.biomoda.com) and Advanced Medical Imaging and Genetics (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer.

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Prostate cancer screening: Another set of new guidelines adds to the confusion

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cryoablation kills breast tumors in mice

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

New federal guidelines on breast cancer screening: Stanford experts disagree

Elsevier releases special issue to mark the 25th anniversary of antiretroviral drug development

Bozeman Deaconess Hospital enters into affiliation agreement with SCCA Network

Researchers demonstrate the safety of potential vaccine against mesothelioma

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Cystoscopy: Cost-effective method of detecting tumors

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

Study on role of recorded ODLs in improving clinical care for low-weight babies: RWJF awards $480,000 grant

Belatacept drug can prevent graft rejection in kidney transplant recipients

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

Biomoda and Amigenics collaborate to advance treatments for lung and other cancer

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Industry Focus: Cell & Gene Therapy eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in